LLY

Business Context and Reporting Period

This Form 10-Q covers Eli Lilly and Company for the quarter and nine months ended September 30, 1995. The reporting period is significantly impacted by the effective completion of the divestiture of the Medical Devices and Diagnostics (MDD) Division, including the split-off of Guidant Corporation and the pending sale of Hybritech. Consequently, MDD results are classified as discontinued operations. The company also announced a definitive agreement to acquire Integrated Medical Systems, Inc. (IMS) in August 1995.

Key Financial Metrics

Margin Analysis: Cost of sales as a percentage of sales improved to 25.7% in Q3 1995 (down from 29.9% in Q3 1994) and 28.0% for the nine months (down from 29.3%). The estimated effective tax rate for 1995 was 29%, compared to approximately 30.6% in 1994.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 8% in Q3 and 19% for the nine months ended September 30, 1995, compared to 1994. Growth was driven by volume increases (8% in Q3, 17% in 9M) and favorable foreign exchange rates. Pharmaceutical sales grew 8% in Q3 and 20% in 9M.
• Discontinued Operations: Net income was heavily influenced by a $910.0 million net gain recognized in Q3 1995 from the divestiture of MDD businesses (Guidant split-off and other sales). This gain is excluded from continuing operations.
• Expense Increases: Research & development expenses rose 19% in Q3 and 27% in 9M, driven by late-stage clinical trials (e.g., raloxifene). Marketing & administrative expenses increased 23% in Q3 and 33% in 9M, largely due to the inclusion of PCS Health Systems and global expansion efforts.
• Interest Expense: Interest expense surged to $75.6 million in Q3 1995 from $15.3 million in Q3 1994, reflecting borrowings associated with the PCS acquisition.
• Product Specifics: Prozac sales reached $580.7 million in Q3 (up 7%). Conversely, U.S. sales of cefaclor dropped 71% due to unexpected generic competition.

Guidance, Outlook, and Risks

• Outlook: Management expects continued growth for Prozac sales through 1995, with total annual sales projected to exceed $2.0 billion. The company anticipates cash generated from operations will be sufficient to fund operating needs, debt service, and dividends.
• Dividends: On October 16, 1995, the Board declared a 100% stock dividend (two-for-one split) and increased the quarterly cash dividend from $0.645 to $0.685 per share (pre-split basis).
• Legal Contingencies: The company faces significant litigation risks, including product liability suits (Prozac, diethylstilbestrol), patent litigation (Humatrope, Humulin), and antitrust actions regarding pricing. As of September 30, 1995, gross liabilities for these matters were approximately $345.5 million, with estimated insurance recoverables of $136.7 million. Management believes these costs will not materially affect financial position but could impact results in a single period.
• Environmental: The company is a potentially responsible party under Superfund for certain sites and has accrued for estimated cleanup costs.
• Acquisitions: The acquisition of IMS is expected to close in December 1995. The purchase price is not expected to be material.

Investor Verification Checklist

• Verify the sustainability of Prozac sales growth given the $2.0 billion annual projection and potential patent expiration timelines.
• Assess the impact of generic competition on cefaclor sales and the likelihood of success in the pending patent infringement litigation.
• Review the status of the IMS acquisition and the final purchase price upon closing in December 1995.
• Monitor the resolution of antitrust and product liability litigation, specifically the potential for costs to exceed current accruals of $345.5 million.
• Confirm the impact of the two-for-one stock split on share count and per-share metrics in subsequent filings.